{"contentid": 488295, "importid": NaN, "name": "BMS present mixed Opdivo and Yervoy data in ESCC", "introduction": "Bristol Myers Squibb has announced top-line results from the Phase III CheckMate -648 trial evaluating Opdivo (nivolumab) plus chemotherapy or alongside Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).", "content": "<p>Bristol Myers Squibb (NYSE: BMY) has announced top-line results from the Phase III CheckMate -648 trial evaluating Opdivo (nivolumab) plus chemotherapy or alongside Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).</p>\n<p>Opdivo plus chemotherapy demonstrated a statistically-significant and clinically-meaningful benefit for the primary and secondary endpoints of overall survival (OS) in patients whose tumors express PD-L1 and in the all-randomized patient population at the pre-specified interim analysis.</p>\n<p>Additionally, Opdivo plus chemotherapy demonstrated a statistically-significant and clinically-meaningful improvement in the primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR) in patients whose tumors express PD-L1.</p>\n<h2>Yervoy combination misses one primary endpoint</h2>\n<p>Meanwhile, Opdivo plus Yervoy also met primary and secondary endpoints by demonstrating statistically-significant and clinically-meaningful improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population.</p>\n<p>However, the combination did not meet the other primary endpoint of progression-free survival by BICR in patients whose tumors express PD-L1.</p>\n<p>Ian Waxman, development lead, gastrointestinal cancers, BMS, said: &ldquo;The results for these Opdivo-based combinations represent a significant advancement for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options.</p>\n<p>&ldquo;This study further demonstrates our commitment to pursue combination strategies that improve outcomes for patients with high unmet need, such as those with gastrointestinal cancers.&rdquo;</p>\n<h2>Growing body of evidence</h2>\n<p>The data from CheckMate -648 build upon those from CheckMate -649, together making Opdivo the first and only PD-1/L1 inhibitor to demonstrate superior first-line survival in upper gastrointestinal cancers across histologies and tumor locations.</p>\n<p>They also add to the existing body of data demonstrating the clinical benefit of Opdivo in esophageal cancer, from the late-line metastatic setting to earlier stages of disease.</p>\n<p>Opdivo's US label currently includes treatment of unresectable advanced, recurrent or metastatic ESCC after previous chemotherapy.&nbsp;</p>\n<p>Regulators in the USA and the European Union are currently evaluating whether to approve Opdivo alongside chemotherapy as a first-line treatment for metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma, based on BMS' CheckMate -649 results. The US Food and Drug Administration is expected to make a decision by May 25.</p>\n<p>&nbsp;</p>", "date": "2021-04-09 11:53:00", "meta_title": NaN, "meta_keywords": "Opdivo, Yervoy, chemotherapy, ESCC, patients, CheckMate, metastatic, primary, survival, results, esophageal, data, significant, PD-L, express, tumors, mixe", "meta_description": "Bristol Myers Squibb has announced topline results from the Phase III CheckMate -648 trial evaluating Opdivo (nivolumab) plus chemotherapy or alongside Yervoy (", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-09 11:38:41", "updated": "2021-04-09 12:47:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/bms-present-mixed-opdivo-and-yervoy-data-in-escc", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bristol-myers-squibb_large.png", "image2id": "bristol-myers-squibb_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Bristol-Myers Squibb", "drug_tag": "Opdivo, Yervoy", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-09 11:53:00"}